EVMN
Evommune, Inc. · Healthcare · Market cap $340.1M
Insiders sold $2.1M net in the last 90 days ·6 sellers, 2 buyers· 8 of 8 sales under Rule 10b5-1 plans· latest Form 4 filed Jul 10, 2026
Insider Buying
$70.2M
reported purchases (SEC code P)
Insider Selling
$2.3M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Latest filing
Jul 10, 2026
Carver Kyle
Evommune, Inc. (EVMN) has 32 SEC Form 4 filings (49 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Jul 10, 2026.
Inside the rolling window, 11 insiders at Evommune, Inc. reported 6 open-market purchases totaling $70.2M and 8 open-market sales totaling $2.3M. Insiders have net sold $2.1M over the trailing 6 months. The most recent open-market filing is a purchase of 1,000 shares by Chief Financial Officer Carver Kyle, dated Jul 8, 2026, worth $13K.
- Industry:Biotechnology
- CEO:Luis C. Pena
- Employees:48
- HQ:Palo Alto, CA, US
- IPO:2025-11-06
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Financial Officer | Purchase | 1,000 | $13K | Jul 10 | -29.1% | SEC ↗ | |
| Director | Purchase | 10,000 | $133K | Jul 9 | -30.6% | SEC ↗ | |
Drew Janice SuzannFirst filing | Chief of Dev. Operations | Sale | 20,000 | $453K | Jun 25 | -61.2% | SEC ↗ |
| Chief Scientific Officer | Sale | 1,488 | $33K | Jun 25 | -61.2% | SEC ↗ | |
| President & CEO | Sale | 7,438 | $169K | Jun 24 | -60.2% | SEC ↗ | |
Patel Jeegar PravinkumarFirst filing | Chief Scientific Officer | Sale | 16,687 | $379K | Jun 3 | -52.5% | SEC ↗ |
Cohen David EFirst filing | Director | Sale | 6,056 | $123K | Jun 3 | -52.5% | SEC ↗ |
Pena Luis C.First filing | President & CEO | Sale | 16,787 | $382K | Jun 3 | -52.5% | SEC ↗ |
Moss Gregory S.First filing | Chief Business & Legal Officer | Sale | 14,223 | $325K | Jun 2 | -52.7% | SEC ↗ |
Carver KyleFirst filing | Chief Financial Officer | Sale | 18,175 | $415K | Jun 1 | — | SEC ↗ |
Hopfner Robert LorneFirst filing | Director, 10% Owner | Purchase | 1,000 | $17K | Dec 22 | — | SEC ↗ |
| Director, 10% Owner | Purchase | 1,250,000 | $20.0M | Nov 12 | — | SEC ↗ | |
LSP 7 Cooperative UAFirst filing | 10% Owner | Purchase | 1,562,500 | $25.0M | Nov 12 | — | SEC ↗ |
Verduyn-van Weegen Felice IsabelFirst filing | Director, 10% Owner | Purchase | 1,562,500 | $25.0M | Nov 12 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does EVMN have?
Evommune, Inc. (EVMN) has 32 SEC Form 4 filings (49 transaction rows) in the rolling 365-day window, disclosed by 11 distinct insiders. Most recent filing: Jul 10, 2026.
When was the most recent SEC Form 4 filing for EVMN?
The most recent Form 4 filing for EVMN on Tracefour is dated Jul 10, 2026.
What is the net insider flow at EVMN over the last 6 months?
Over the trailing 180 days, insiders at EVMN have net sold $2.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at EVMN in the current window?
Inside the rolling window, insiders at EVMN bought $70.2M and sold $2.3M based on SEC Form 4 filings.
Can I get alerts for EVMN insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Evommune, Inc. (EVMN). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Evommune, Inc. is in the Healthcare sector.